NCT00450307View on ClinicalTrials.gov

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Neuroblastoma
Interventions
BIOLOGICAL

monoclonal antibody 3F8

BIOLOGICAL

sargramostim

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00450307 - Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma | Biotech Hunter | Biotech Hunter